Glenmark Pharmaceuticals has announced the appointment of Alessandro Riva as the CEO of its new innovation company.
Mr. Riva is currently Executive Vice President, Oncology Therapeutics and Cell Therapy for Gilead Sciences. The appointment is effective April 2, 2019.
Glenmark Pharmaceuticals announced on February 14, 2019, the in-principle approval from its Board of Directors to spin off the innovation business into a new company headquartered in the US. “The new company will be a wholly-owned subsidiary of Glenmark and will operate with Alessandro Riva as the CEO, a management team and an independent Board of Directors,” the company said in a stock exchange filing.
“We are pleased that Alessandro will assume the role of CEO of the new innovation business,” said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals in a statement. “His extensive and diverse industry experience leading global R&D will no doubt be invaluable in driving our pipeline towards commercialization. We are excited for this major step as a company and are confident Alessandro’s talent and leadership will shape the innovation business into a major global biotech company,” he said. Prior to joining Gilead, he was with Novartis where he was the Executive Vice President and Head of Global Oncology Development and Medical Affairs. He also served as Interim President of the Novartis Oncology Business Unit during the acquisition of GSK Oncology. Prior to his time at Novartis, he held leadership roles with Rhône-Poulenc Rorer and Aventis, France. “The novel technology and diverse pipeline, which includes clinical-stage candidates on track to progress rapidly, has the potential to differentiate in areas of unmet need,” said Mr. Riva. The new innovation company will be headquartered in Paramus, New Jersey. Global locations include two R&D centers in Switzerland, the R&D center at Mahape, Navi Mumbai, India.
Source : www.thehindu.com
Published on: March 13, 2019